Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Blacksmith who wrote (14804)	10/26/1998 8:26:00 PM
From: xcr600	Respond to of 18691

re: BTIM from Briefing.com (via AOL) (DAYTRADER) Shares of Berkeley, CA-based biotech company, BioTime Inc (BTIM 9 1/4 -1 3/8), have fallen 13% on the session after boutique firm Asensio & Company cautioned investors that BTIM management is fostering expectations the company's New Drug Application for Hextend is receiving FDA priority review. Comments come after BTIM shares rallied last week, spiking from the $9 level to $13 per share. According to Asensio, if the Hextend's NDA had been reviewed on a priority basis, BioTime would have received FDA notification concerning approval by now. The firm does not believe Hextend is the product BTIM is promoting it to be. Asensio expects BioTime shares to trade below $1 per share. Briefing.com has no opinion on BTIM as a company or the market potential of Hextend . However, we do believe that this stock may present a trading opportunity, based solely on the issue's high short-interest. With almost 20% of its outstanding shares sold short and a Short/Interest ratio of 30 days, BTIM is the type of stock that short-killers love, as the potential is always present for a squeeze.